LGALS1 and neoplasm: Other studies have shown the ability of LGALS1 to induce apoptosis in T-cells and prevent T-cell migration across the tumor endothelium (31, 32), while the addition of recombinant LGALS1 prolonged the survival of the kidney allografts and was required to induce tolerance in B-cells, in preclinical models (33, 34).